


Workshop on Characterization of Nanomaterials for Medical and Health Applications

Jointly sponsored by ASTM, NCI, NIST and U.S. FDA


May 19, 2005 - Reno, NV

http://www.astm.org/MEETINGS/COMMIT/E56wkshp.html



Workshop Questions

- 1. Based on the history of the in-vitro characterization of materials for drug applications, what characteristics are important for consideration of nanomaterials in this application? Are there any characteristics not previously important that are new for nanomaterials?
- 2. Given the literature available on characterization of nanomaterials for use as pharmaceuticals, what are the characteristics for which we should we try to develop standard test methods for the in-vitro characterization of nanomaterials for drug applications?



Workshop Questions

- 3. What infrastructure support does the nanotech researcher need to better characterize their nanomaterial against these standard methods? (e.g., access to instrumentation, batch-to-batch analysis, experimental design, assay development/validation).
- 4. With respect to the above questions, how do we design the validation experiment for the methods we determine are important? What 3rd party entity will be acceptable/"recognized" to evaluate the validation experiment? Can we do the validation as an "ASTM E56 standards community"?